PRF Technologies Ltd.
PRFX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRFX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRFX
PRF Technologies Ltd. (PRFX) is a pre-revenue biopharmaceutical company developing drug candidates including OcuRing™-K and PRF-110, with a recently acquired DeepSolar business, and faces significant capital needs and operational risks.
Key risk: Going concern risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 12 clinical trials for PRF Technologies Ltd..
PRF Technologies Ltd. (PRFX) is a pre-revenue biopharmaceutical company developing drug candidates including OcuRing™-K and PRF-110, with a recently acquired DeepSolar business, and faces significant capital needs and operational risks.
- As of December 31, 2025, PRF Technologies had cash and cash equivalents of $4.1 million and an accumulated deficit of approximately $61.3 million [sec · filed 2026-03-26].
- The company has not yet commercialized any drug candidates or its drug delivery system, and its DeepSolar business is in initial commercialization stages [sec · filed 2026-03-26].
- Net losses were $4.8 million for the year ended December 31, 2025, compared to $14.6 million in 2024 [sec · filed 2026-03-26].
- PRF Technologies has identified a material weakness in internal control over financial reporting, which could affect the reliability of its financial statements [sec · filed 2026-03-26].
What works
- The company is advancing OcuRing™-K and PRF-110 through clinical trials, which could address unmet medical needs if successful [sec · filed 2026-03-26].
- PRF Technologies has a recently acquired DeepSolar business that is in initial commercialization, potentially diversifying revenue sources [sec · filed 2026-03-26].
What to weigh
- PRF Technologies has never generated significant revenues and expects to continue incurring losses for the foreseeable future [sec · filed 2026-03-26].
- The company will need substantial additional funding to support its development and commercialization efforts, and such capital may not be available on acceptable terms [sec · filed 2026-03-26].
- A material weakness in internal control over financial reporting has been identified, posing a risk to accurate financial reporting [sec · filed 2026-03-26].
- The company operates in highly regulated and competitive markets (biopharmaceutical and solar energy), where regulatory approval and market acceptance are uncertain [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
The company has not commercialized any drug candidates and may never become profitable.
“have not yet commercialized our drug candidates, including OcuRing™-K, or our drug delivery system and cannot be sure that we will ever be able to do so”
SEC filings · March 26, 2026
The company has identified a material weakness in internal control over financial reporting.
“We have identified a material weakness in our internal control over financial reporting.”
SEC filings · March 26, 2026
The company expects to continue incurring significant losses and increasing expenses.
“We expect to continue to incur significant expenses and increasing losses for next several years.”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — The company has a history of losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-03-26].
- Capital needs — PRF Technologies will need substantial additional funding to support operations and clinical trials; capital may not be available on acceptable terms [sec · filed 2026-03-26].
- Clinical trial delays — Patient enrollment and trial completion are uncertain, which could delay or prevent product development [sec · filed 2026-03-26].
- Internal control weakness — A material weakness in internal control over financial reporting could impair the reliability of financial statements [sec · filed 2026-03-26].
What to watch
- Progress and enrollment in clinical trials for OcuRing™-K and PRF-110 [sec · filed 2026-03-26].
- Ability to raise additional capital through equity financings or partnerships [sec · filed 2026-03-26].
- Remediation of the material weakness in internal control over financial reporting [sec · filed 2026-03-26].
- Commercialization milestones for the DeepSolar business [sec · filed 2026-03-26].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run PRF Technologies Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PRF Technologies Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.7 months
D/E 0.32 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$30K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 13,220 | $27K |
| morgan stanley | 1,611 | $3K |
| osaic holdings, inc. | 40 | $80 |
Short Interest
as of Apr 21, 2026- % of float
- 6.9%
- Days to cover
- 1.9
- Shares short
- 58,396
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRFX short interestFrequently asked questions
What is the AI investment thesis for PRF Technologies Ltd.?
PRF Technologies Ltd. (PRFX) is a pre-revenue biopharmaceutical company developing drug candidates including OcuRing™-K and PRF-110, with a recently acquired DeepSolar business, and faces significant capital needs and operational risks.
Who is the CEO of PRF Technologies Ltd.?
Mr. Efraim Cohen-Arazi is the chief executive officer of PRF Technologies Ltd. (PRFX).
Where is PRF Technologies Ltd. headquartered?
PRF Technologies Ltd. (PRFX) is headquartered in Tel Aviv-Yafo, Israel.
What therapeutic areas does PRF Technologies Ltd. focus on?
PRF Technologies Ltd. develops therapies across Oncology, Neurology, Immunology, Cardiovascular, Pain, Dermatology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.